EMA — authorised 18 August 2021
- Marketing authorisation holder: ASTELLAS PHARMA EUROPE B.V.
- Status: approved
🇪🇺 Evrenzo in European Union
EMA authorised Evrenzo on 18 August 2021
Marketing authorisations
EMA — authorised 18 August 2021
- Application: EMEA/H/C/004871
- Marketing authorisation holder: Astellas Pharma Europe B.V.
- Local brand name: Evrenzo
- Indication: Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
- Status: approved
Evrenzo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in European Union
Frequently asked questions
Is Evrenzo approved in European Union?
Yes. EMA authorised it on 18 August 2021; EMA authorised it on 18 August 2021.
Who is the marketing authorisation holder for Evrenzo in European Union?
ASTELLAS PHARMA EUROPE B.V. holds the EU marketing authorisation.